U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}
Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. Fluticasone furoate is a anti-allergic agents that is FDA approved for the treatment of symptoms of seasonal and perennial allergic rhinitis, asthma and for reducing exacerbations in patients with chronic obstructive pulmonary disease. Fluticasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor. The clinical relevance of these findings is unknown. The most common adverse reactions (>1% incidence) included headache, epistaxis, pharyngolaryngeal pain, nasal ulceration, back pain, pyrexia, and cough. Coadministration of ritonavir is not recommended. Use caution with coadministration of other potent CYP3A4 inhibitors, such as ketoconazole.
Status:
First approved in 1987

Class (Stereo):
CHEMICAL (ABSOLUTE)



Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. When glucocorticoids are discontinued, asthma stability may persist for several days or longer. Mometasone has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. Mometasone inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis. ELOCON Lotion (Mometasone) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Status:
Investigational
Source:
INN:icometasone enbutate
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)



Icometasone (CL09) is a synthetic glucocorticoid corticosteroid. It is a metabolite of Mometasone Furoate. The binding on human serum albumin was shown to be non saturable, suggesting that other proteins were involved in CL09 binding. This binding was demonstrated to be reversible. CL09 was extensively metabolized since no unchanged CL09 was recovered in bile or urine and at least nine metabolites have been detected. It was studied in Europe as an anti-asthmatic agent but investigation is discontinued.
Status:
Investigational
Source:
INN:fubrogonium iodide
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Fubromegan, a ganglionic blocking agent as an iodide salt, FUBROGONIUM IODIDE was used in Russia in patients with peptic ulcer and in the symptomatic therapy of patients with pneumoconioses. The antispasmodic effect of fubromegan was due to the effect on m- and n-cholinergic structures of smooth muscles and ganglia.
Status:
Investigational
Source:
INN:furbucillin
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Furbucillin is a synthetic antibacterial agent that has never been marketed. Information about the current use of this drug is not available.
Status:
Investigational
Source:
INN:furostilbestrol
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Furostilbestrol (diethylstilbestrol di(2-furoate)) is a synthetic estrogen that was first described in 1952. It is an ester of diethylstilbestrol (DES), a synthetic estrogen that was prescribed to pregnant women until 1971 to prevent miscarriages and that has been associated with cancer, birth defects and several other developmental abnormalities. Furostilbestrol was never marketed.